search
Back to results

Effect of the Use of Probiotic S. Boulardii on Acute Viral Inflammatory Diarrhea Diagnosed With Multiplex PCR.

Primary Purpose

Viral Diarrhea

Status
Completed
Phase
Not Applicable
Locations
Mexico
Study Type
Interventional
Intervention
Saccharomyces boulardii (Floratil 600mg)
3 capsules of placebo
Sponsored by
Instituto Mexicano del Seguro Social
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Viral Diarrhea

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • patients who give their informed consent,
  • over 18 years of age,
  • leukocytes in the stool,
  • confirmed diagnosis of viral infection using the multiplex PCR

Exclusion Criteria:

  • Confirmed diagnosis of infection by bacteria and/or parasites, associated or not with viral etiology;
  • autoimmune diseases or immunosuppressive treatment;
  • previous administration of antibiotic treatment during the last 7 days;
  • consumption of any type of probiotic in the last 7 days;
  • known allergy to probiotic containing S. boulardii;
  • Inflammatory Bowel Disease;
  • positive test or clinical positivity to the current operational definition for severe acute respiratory syndrome coronavirus 2 (SARS-COV-2).
  • patients who do not have medical insurance.

Sites / Locations

  • Hospital Puerta de Hierro Sur

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

S. boulardii

Placebo

Arm Description

treatment arm group (3 capsules of Floratil 200mg®/day)

control group (3 capsules of placebo/day)

Outcomes

Primary Outcome Measures

Number of subjects with S. boulardii on acute inflammatory viral diarrhea diagnosed with Multiplex PCR technique as treatment that have a change in the severity of their symptoms measured with PGIS and PGIC assessments at day 4 and day 8.
The Patient Global Impression scale (PGI) is the Patient-reported outcomes counterpart to the Clinical Global Impressions scale. The PGIS are 1-item questionnaire that ask an individual patient to rate the severity of a specific condition (single-state scales) at baseline and or to rate at endpoint the perceived change in his/her condition in response to therapy; in the other hand PGIC measures change in clinical status.

Secondary Outcome Measures

Number of subjects with acute inflammatory viral diarrhea treated in the gastroenterology and coloproctology area
To determine the incidence of viral pathogens in patients diagnosed with acute inflammatory viral diarrhea treated in the gastroenterology and coloproctology area during the 12 month period; measured by applying the multiplex PCR test to determine the causative pathogen.
Number of subjects presenting associated symptoms in both groups in day 4 and 8 after diagnosis
To identify the incidence of associated symptoms, such as: fever and abdominal pain; assessed using the patient's daily record.

Full Information

First Posted
December 14, 2021
Last Updated
September 29, 2023
Sponsor
Instituto Mexicano del Seguro Social
search

1. Study Identification

Unique Protocol Identification Number
NCT05226052
Brief Title
Effect of the Use of Probiotic S. Boulardii on Acute Viral Inflammatory Diarrhea Diagnosed With Multiplex PCR.
Official Title
Effect of the Use of Probiotic Saccharomyces Boulardii on Acute Viral Inflammatory Diarrhea Diagnosed With Multiplex PCR Technique, Randomized Clinical Trial (RCT).
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Completed
Study Start Date
December 21, 2020 (Actual)
Primary Completion Date
January 3, 2022 (Actual)
Study Completion Date
January 3, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Instituto Mexicano del Seguro Social

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Acute diarrhea (AD) has been a public health problem throughout the history of Mexico. According to the epidemiological surveillance system, between 2008-2017, five to six million new cases of AD occurred per year. Clinical presentation of viral gastroenteritis ranges from an asymptomatic state to diarrhea with severe dehydration. Viral etiology can be difficult to differentiate from those of gastroenteritis caused by enteric bacteria based solely on clinical presentation, especially due to the presence of leukocytes in stool, since it was thought that only diarrhea of bacterial etiology was present and what defines it as acute inflammatory diarrhea; therefore, laboratory studies are essential to make a specific diagnosis. In addition to methylene blue test traditionally performed to describe the presence of leukocytes in stool, multiplex PCR is an automated system in which the extraction, amplification and detection of nucleic acid occurs in a single closed pouch. The panel includes for the etiological identification of bacteria, parasites and viruses. Probiotics are effective for acute infectious diarrhea caused by bacteria, but there are inconsistent results on the effectiveness of probiotics for diarrhea caused by viruses. It is important to note that there are no studies in the adult population with acute diarrhea of viral etiology identified by PCR Multiplex in our environment and the use of probiotics to reduce the period of convalescence. Mexico also lacks for detection tests to identify the pathogen, that can be used routinely in clinical practice, as other countries has shown the economical, clinical outcomes and patient satisfaction results with it. In a review, S. boulardii shows an effectiveness in 4 of the 6 studies where it was used as a treatment in acute adult viral diarrhea, where it was used as a treatment. Based on this review, because it considers the adult population, it will be used S. boulardii as a treatment in patients diagnosed with acute viral diarrhea, to reduce the days of presence of associated symptoms. The Patient Global Impression scale (PGI) is the Patient-reported outcomes counterpart to the Clinical Global Impressions scale. The PGIS are 1-item questionnaire that ask an individual patient to rate the severity of a specific condition at baseline and or to rate at endpoint the perceived change in his/her condition in response to therapy; in the other hand PGIC measures change in clinical status
Detailed Description
Acute diarrhea (AD) has been a public health problem throughout the history of Mexico. According to the epidemiological surveillance system, between 2008 and 2017, five to six million new cases of AD occurred per year. The clinical presentation of viral gastroenteritis ranges from an asymptomatic state to diarrhea with severe dehydration. Viral etiology can be difficult to differentiate from those of gastroenteritis caused by enteric bacteria based solely on clinical presentation, especially due to the presence of leukocytes in stool, since it was thought that only diarrhea of bacterial etiology was present and what defines it as acute inflammatory diarrhea; therefore, laboratory studies are essential to make a specific diagnosis. In addition to methylene blue test traditionally performed to describe the presence of leukocytes in stool, Multiplex Polymerase Chain Reaction (PCR) is an automated system in which the extraction, amplification and detection of nucleic acid occurs in a single closed pouch. The panel includes for the etiological identification of bacteria, parasites and viruses. Probiotics are effective for acute infectious diarrhea caused by bacteria, but there are inconsistent results on the effectiveness of probiotics for diarrhea caused by viruses. It is important to note that there are no studies in the adult population with acute diarrhea of viral etiology identified by PCR Multiplex in our environment and the use of probiotics to reduce the period of convalescence. Mexico also lacks for detection tests to identify the pathogen, that can be used routinely in clinical practice, as other countries has shown the economical, clinical outcomes and patient satisfaction results with it. In a review, S. boulardii shows an effectiveness in 4 of the 6 studies where it was used as a treatment in acute adult viral diarrhea, where it was used as a treatment. Based on this review, because it considers the adult population, it wll be used S. boulardii as a treatment in patients diagnosed with acute viral diarrhea, to reduce the days of presence of associated symptoms. The Patient Global Impression scale (PGI) is the Patient-reported outcomes counterpart to the Clinical Global Impressions scale. The Patient Global Impression scale of Severity (PGIS) are 1-item questionnaire that ask an individual patient to rate the severity of a specific condition (single-state scales) at baseline and or to rate at endpoint the perceived change in his/her condition in response to therapy; in the other hand The Patient Global Impression scale of Change (PGIC) measures change in clinical status. Research question: What is the effect of the use of probiotic S. boulardii on acute inflammatory diarrhea of viral etiology diagnosed with multiplex PCR technique? Hypothesis: The use of S. boulardii in patients with acute viral inflammatory diarrhea diagnosed with the Multiplex PCR technique will decrease the days of associated symptoms and self-reported improvement. Main objective: To analyze the effect of the use of S. boulardii on acute inflammatory viral diarrhea diagnosed with the Multiplex PCR technique. Specifics: 1. To determine the incidence of viral pathogens in patients diagnosed with acute inflammatory viral diarrhea treated in the gastroenterology and coloproctology area. 2. To identify the incidence of associated symptoms in both groups in day 4 and 8 after diagnosis. 3. Compare the days of self-reported improvement by the patient between both groups using the PGIS and PGIC surveys.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Viral Diarrhea

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Randomized, double-blind clinical trial
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Masking Description
: The person delegated to assigns treatment is the nurse of the medical office. Assignment will be done using a simple excel algorithm. The cans are numbered sequentially. The blindness will be broken until the statistical analysis is completed
Allocation
Randomized
Enrollment
46 (Actual)

8. Arms, Groups, and Interventions

Arm Title
S. boulardii
Arm Type
Experimental
Arm Description
treatment arm group (3 capsules of Floratil 200mg®/day)
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
control group (3 capsules of placebo/day)
Intervention Type
Dietary Supplement
Intervention Name(s)
Saccharomyces boulardii (Floratil 600mg)
Other Intervention Name(s)
PGIC and PGIS assessment
Intervention Description
PGIC and PGIS assessment
Intervention Type
Dietary Supplement
Intervention Name(s)
3 capsules of placebo
Other Intervention Name(s)
PGIC and PGIS assessment
Intervention Description
PGIC and PGIS assessment
Primary Outcome Measure Information:
Title
Number of subjects with S. boulardii on acute inflammatory viral diarrhea diagnosed with Multiplex PCR technique as treatment that have a change in the severity of their symptoms measured with PGIS and PGIC assessments at day 4 and day 8.
Description
The Patient Global Impression scale (PGI) is the Patient-reported outcomes counterpart to the Clinical Global Impressions scale. The PGIS are 1-item questionnaire that ask an individual patient to rate the severity of a specific condition (single-state scales) at baseline and or to rate at endpoint the perceived change in his/her condition in response to therapy; in the other hand PGIC measures change in clinical status.
Time Frame
8 days
Secondary Outcome Measure Information:
Title
Number of subjects with acute inflammatory viral diarrhea treated in the gastroenterology and coloproctology area
Description
To determine the incidence of viral pathogens in patients diagnosed with acute inflammatory viral diarrhea treated in the gastroenterology and coloproctology area during the 12 month period; measured by applying the multiplex PCR test to determine the causative pathogen.
Time Frame
365 days
Title
Number of subjects presenting associated symptoms in both groups in day 4 and 8 after diagnosis
Description
To identify the incidence of associated symptoms, such as: fever and abdominal pain; assessed using the patient's daily record.
Time Frame
8 days
Other Pre-specified Outcome Measures:
Title
Compare the days of self-reported improvement by the patient between both groups using the PGIS and PGIC surveys.
Description
Compare the days of self-reported improvement by the patient between both groups using the PGIS and PGIC surveys.
Time Frame
8 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: patients who give their informed consent, over 18 years of age, leukocytes in the stool, confirmed diagnosis of viral infection using the multiplex PCR Exclusion Criteria: Confirmed diagnosis of infection by bacteria and/or parasites, associated or not with viral etiology; autoimmune diseases or immunosuppressive treatment; previous administration of antibiotic treatment during the last 7 days; consumption of any type of probiotic in the last 7 days; known allergy to probiotic containing S. boulardii; Inflammatory Bowel Disease; positive test or clinical positivity to the current operational definition for severe acute respiratory syndrome coronavirus 2 (SARS-COV-2). patients who do not have medical insurance.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Alejandro Gonzalez Ojeda, MD, PhD
Organizational Affiliation
Instituto Mexica del Seguro Social
Official's Role
Study Director
Facility Information:
Facility Name
Hospital Puerta de Hierro Sur
City
Tlajomulco De Zúñiga
State/Province
Jalisco
ZIP/Postal Code
45640
Country
Mexico

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
11136781
Citation
Savola KL, Baron EJ, Tompkins LS, Passaro DJ. Fecal leukocyte stain has diagnostic value for outpatients but not inpatients. J Clin Microbiol. 2001 Jan;39(1):266-9. doi: 10.1128/JCM.39.1.266-269.2001.
Results Reference
result
PubMed Identifier
17306006
Citation
Villarruel G, Rubio DM, Lopez F, Cintioni J, Gurevech R, Romero G, Vandenplas Y. Saccharomyces boulardii in acute childhood diarrhoea: a randomized, placebo-controlled study. Acta Paediatr. 2007 Apr;96(4):538-41. doi: 10.1111/j.1651-2227.2007.00191.x. Epub 2007 Feb 14.
Results Reference
result
PubMed Identifier
33927201
Citation
Wang LP, Zhou SX, Wang X, Lu QB, Shi LS, Ren X, Zhang HY, Wang YF, Lin SH, Zhang CH, Geng MJ, Zhang XA, Li J, Zhao SW, Yi ZG, Chen X, Yang ZS, Meng L, Wang XH, Liu YL, Cui AL, Lai SJ, Liu MY, Zhu YL, Xu WB, Chen Y, Wu JG, Yuan ZH, Li MF, Huang LY, Li ZJ, Liu W, Fang LQ, Jing HQ, Hay SI, Gao GF, Yang WZ; Chinese Centers for Disease Control and Prevention (CDC) Etiology of Diarrhea Surveillance Study Team. Etiological, epidemiological, and clinical features of acute diarrhea in China. Nat Commun. 2021 Apr 29;12(1):2464. doi: 10.1038/s41467-021-22551-z.
Results Reference
result
PubMed Identifier
24242161
Citation
Pang XL, Preiksaitis JK, Lee BE. Enhanced enteric virus detection in sporadic gastroenteritis using a multi-target real-time PCR panel: a one-year study. J Med Virol. 2014 Sep;86(9):1594-601. doi: 10.1002/jmv.23851. Epub 2013 Nov 14.
Results Reference
result
PubMed Identifier
29262044
Citation
Chiejina M, Samant H. Viral Diarrhea. 2022 Jun 1. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from http://www.ncbi.nlm.nih.gov/books/NBK470525/
Results Reference
result
PubMed Identifier
26965886
Citation
Farfan M, Piemonte P, Labra Y, Henriquez J, Candia E, Torres JP. [Filmarray GI TM panel for detection of enteric pathogens in stool samples: preliminary experience]. Rev Chilena Infectol. 2016 Feb;33(1):89-91. doi: 10.4067/S0716-10182016000100016. Spanish.
Results Reference
result
PubMed Identifier
31869558
Citation
Olaiz-Fernandez GA, Gomez-Pena EG, Juarez-Flores A, Vicuna-de Anda FJ, Morales-Rios JE, Carrasco OF. [Historical overview of acute infectious diarrhea in Mexico and future preventive strategies]. Salud Publica Mex. 2020 Jan-Feb;62(1):25-35. doi: 10.21149/10002. Spanish.
Results Reference
result
PubMed Identifier
31314211
Citation
Palacio-Mejia LS, Rojas-Botero M, Molina-Velez D, Garcia-Morales C, Gonzalez-Gonzalez L, Salgado-Salgado AL, Hernandez-Avila JE, Hernandez-Avila M. Overview of acute diarrheal disease at the dawn of the 21st century: The case of Mexico. Salud Publica Mex. 2020 Jan-Feb;62(1):14-24. doi: 10.21149/9954.
Results Reference
result
PubMed Identifier
22430951
Citation
Matthijnssens J, Otto PH, Ciarlet M, Desselberger U, Van Ranst M, Johne R. VP6-sequence-based cutoff values as a criterion for rotavirus species demarcation. Arch Virol. 2012 Jun;157(6):1177-82. doi: 10.1007/s00705-012-1273-3. Epub 2012 Mar 20.
Results Reference
result
PubMed Identifier
24023773
Citation
Lanata CF, Fischer-Walker CL, Olascoaga AC, Torres CX, Aryee MJ, Black RE; Child Health Epidemiology Reference Group of the World Health Organization and UNICEF. Global causes of diarrheal disease mortality in children <5 years of age: a systematic review. PLoS One. 2013 Sep 4;8(9):e72788. doi: 10.1371/journal.pone.0072788. eCollection 2013.
Results Reference
result
PubMed Identifier
24981041
Citation
Ahmed SM, Hall AJ, Robinson AE, Verhoef L, Premkumar P, Parashar UD, Koopmans M, Lopman BA. Global prevalence of norovirus in cases of gastroenteritis: a systematic review and meta-analysis. Lancet Infect Dis. 2014 Aug;14(8):725-730. doi: 10.1016/S1473-3099(14)70767-4. Epub 2014 Jun 26.
Results Reference
result
PubMed Identifier
30586435
Citation
Sniffen JC, McFarland LV, Evans CT, Goldstein EJC. Choosing an appropriate probiotic product for your patient: An evidence-based practical guide. PLoS One. 2018 Dec 26;13(12):e0209205. doi: 10.1371/journal.pone.0209205. eCollection 2018.
Results Reference
result
PubMed Identifier
21069673
Citation
Allen SJ, Martinez EG, Gregorio GV, Dans LF. Probiotics for treating acute infectious diarrhoea. Cochrane Database Syst Rev. 2010 Nov 10;2010(11):CD003048. doi: 10.1002/14651858.CD003048.pub3.
Results Reference
result

Learn more about this trial

Effect of the Use of Probiotic S. Boulardii on Acute Viral Inflammatory Diarrhea Diagnosed With Multiplex PCR.

We'll reach out to this number within 24 hrs